Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (62)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Prentice, A. G.
Right arrow Articles by Oliver, D. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Prentice, A. G.
Right arrow Articles by Oliver, D. A.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy (1995) 36, 657-663
© 1995 The British Society for Antimicrobial Chemotherapy


other

Multiple dose pharmacokinetics of an oral solution of itraconazole in patients receiving chemotherapy for acute myeloid leukaemia

Archibald G. Prenticea, David W. Warnocka,*, Stephen A. N. Johnsonc, Peter C. Taylord and Debra A. Oliverb

aDepartment of Haematology Derriford Hospital, Plymouth PL6 SDH; bPHLS Mycology Reference Laboratory Public Health Laboratory, Bristol BS2 8EL; cDepartment of Haematology Musgrove Park Hospital, Taunton TA1 5DB; dDepartment of Haematology Rotherham District General Hospital, Rotherham S602UD, UK

returned 22 November 1994; accepted 5 May 1995


*Corresponding author

The multiple dose pharmacokinetics of a solution of itraconazole given orally were measured in an open study of 20 patients undergoing remission induction chemotherapy for acute myeloid leukaemia. Patients were given itraconazole 5 mg/kg od, 2.5 mg/kg bd, 2.5 mg/kg odor 1.25 mg/kg bd. The mean daily dose of itraconazole was 407 mg for patients receiving 5 mg/kg/day and 148 mg in patients receiving 2.5 mg/kg/day. Mean concentrations of 493 and 495 µ/L were achieved on day 8 in patients who received 5 mg/kg/d od or 2.5 mg/kg bd itraconazole respectively. However, mean concentrations were significantly lower for those who received 2.5 mg/kg od itraconazole being 110 µg/L on day 8. Mean areas under the serum-concentration time curves were also markedly higher in patients receiving 5 mg/kg/day than in those receiving 2.5 mg/kg/day itraconazole and were 22,382 and 5615 µg.h/L on day 15 respectively. These findings suggest that the serum concentrations attained with an oral solution of 5 mg/kg itraconazole either once daily or in two divided doses are suitable for antifungal prophylaxis in patients receiving chemotherapy for acute myeloid leukaemia.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
JCOHome page
M. Michallet and J. I. Ito
Approaches to the Management of Invasive Fungal Infections in Hematologic Malignancy and Hematopoietic Cell Transplantation
J. Clin. Oncol., July 10, 2009; 27(20): 3398 - 3409.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
E. Robenshtok, A. Gafter-Gvili, E. Goldberg, M. Weinberger, M. Yeshurun, L. Leibovici, and M. Paul
Antifungal Prophylaxis in Cancer Patients After Chemotherapy or Hematopoietic Stem-Cell Transplantation: Systematic Review and Meta-Analysis
J. Clin. Oncol., December 1, 2007; 25(34): 5471 - 5489.
[Abstract] [Full Text] [PDF]


Home page
Antimicrob. Agents Chemother.Home page
G. Krishna, A. Sansone-Parsons, M. Martinho, B. Kantesaria, and L. Pedicone
Posaconazole Plasma Concentrations in Juvenile Patients with Invasive Fungal Infection
Antimicrob. Agents Chemother., March 1, 2007; 51(3): 812 - 818.
[Abstract] [Full Text] [PDF]


Home page
J Antimicrob ChemotherHome page
A. Glasmacher, O. Cornely, A. J. Ullmann, U. Wedding, H. Bodenstein, H. Wandt, C. Boewer, R. Pasold, H.-H. Wolf, M. Hanel, et al.
An open-label randomized trial comparing itraconazole oral solution with fluconazole oral solution for primary prophylaxis of fungal infections in patients with haematological malignancy and profound neutropenia
J. Antimicrob. Chemother., February 1, 2006; 57(2): 317 - 325.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
A. Glasmacher, A. Prentice, M. Gorschluter, S. Engelhart, C. Hahn, B. Djulbegovic, and I. G.H. Schmidt-Wolf
In Reply:
J. Clin. Oncol., December 20, 2005; 23(36): 9429 - 9432.
[Full Text] [PDF]


Home page
BloodHome page
K. A. Marr, F. Crippa, W. Leisenring, M. Hoyle, M. Boeckh, S. A. Balajee, W. G. Nichols, B. Musher, and L. Corey
Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants
Blood, February 15, 2004; 103(4): 1527 - 1533.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
A. Glasmacher, A. Prentice, M. Gorschluter, S. Engelhart, C. Hahn, B. Djulbegovic, and I. G.H. Schmidt-Wolf
Itraconazole Prevents Invasive Fungal Infections in Neutropenic Patients Treated for Hematologic Malignancies: Evidence From a Meta-Analysis of 3,597 Patients
J. Clin. Oncol., December 15, 2003; 21(24): 4615 - 4626.
[Abstract] [Full Text] [PDF]


Home page
Antimicrob. Agents Chemother.Home page
A. H. Groll, L. Wood, M. Roden, D. Mickiene, C. C. Chiou, E. Townley, L. Dad, S. C. Piscitelli, and T. J. Walsh
Safety, Pharmacokinetics, and Pharmacodynamics of Cyclodextrin Itraconazole in Pediatric Patients with Oropharyngeal Candidiasis
Antimicrob. Agents Chemother., August 1, 2002; 46(8): 2554 - 2563.
[Abstract] [Full Text] [PDF]


Home page
Antimicrob. Agents Chemother.Home page
C. Schmitt, Y. Perel, J.-l. Harousseau, S. Lemerle, E. Chwetzoff, J.-P. le Moing, and J.-C. Levron
Pharmacokinetics of Itraconazole Oral Solution in Neutropenic Children during Long-Term Prophylaxis
Antimicrob. Agents Chemother., May 1, 2001; 45(5): 1561 - 1564.
[Abstract] [Full Text]


Home page
Antimicrob. Agents Chemother.Home page
M. A. Boogaerts, J. Maertens, R. Van Der Geest, A. Bosly, J.-L. Michaux, A. Van Hoof, M. Cleeren, R. Wostenborghs, and K. De Beule
Pharmacokinetics and Safety of a 7-Day Administration of Intravenous Itraconazole followed by a 14-Day Administration of Itraconazole Oral Solution in Patients with Hematologic Malignancy
Antimicrob. Agents Chemother., March 1, 2001; 45(3): 981 - 985.
[Abstract] [Full Text]


Home page
Antimicrob. Agents Chemother.Home page
J. L. Harousseau, A. W. Dekker, A. Stamatoullas-Bastard, A. Fassas, W. Linkesch, J. Gouveia, R. De Bock, M. Rovira, W. F. Seifert, H. Joosen, et al.
Itraconazole Oral Solution for Primary Prophylaxis of Fungal Infections in Patients with Hematological Malignancy and Profound Neutropenia: a Randomized, Double-Blind, Double-Placebo, Multicenter Trial Comparing Itraconazole and Amphotericin B
Antimicrob. Agents Chemother., July 1, 2000; 44(7): 1887 - 1893.
[Abstract] [Full Text]


Home page
Clin. Microbiol. Rev.Home page
D. J. Sheehan, C. A. Hitchcock, and C. M. Sibley
Current and Emerging Azole Antifungal Agents
Clin. Microbiol. Rev., January 1, 1999; 12(1): 40 - 79.
[Abstract] [Full Text] [PDF]


Home page
Antimicrob. Agents Chemother.Home page
J. A. Barone, B. L. Moskovitz, J. Guarnieri, A. E. Hassell, J. L. Colaizzi, R. H. Bierman, and L. Jessen
Enhanced Bioavailability of Itraconazole in Hydroxypropylbeta -Cyclodextrin Solution versus Capsules in Healthy Volunteers
Antimicrob. Agents Chemother., July 1, 1998; 42(7): 1862 - 1865.
[Abstract] [Full Text]


Home page
Antimicrob. Agents Chemother.Home page
L. de Repentigny, J. Ratelle, J.-M. Leclerc, G. Cornu, E. M. Sokal, P. Jacqmin, and K. de Beule
Repeated-Dose Pharmacokinetics of an Oral Solution of Itraconazole in Infants and Children
Antimicrob. Agents Chemother., February 1, 1998; 42(2): 404 - 408.
[Abstract] [Full Text]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.